Theravance begins TD-9855 Phase 2 study in fibromyalgia patients
The proof-of-concept study will randomize around 375 fibromyalgia patients with TD-9855 or placebo, once a day for nine weeks, and evaluate the safety and efficacy of two TD-9855
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.